EE05148B1 - Rasvhapete terapeutilised kombinatsioonid - Google Patents
Rasvhapete terapeutilised kombinatsioonidInfo
- Publication number
- EE05148B1 EE05148B1 EEP200200718A EEP200200718A EE05148B1 EE 05148 B1 EE05148 B1 EE 05148B1 EE P200200718 A EEP200200718 A EE P200200718A EE P200200718 A EEP200200718 A EE P200200718A EE 05148 B1 EE05148 B1 EE 05148B1
- Authority
- EE
- Estonia
- Prior art keywords
- fatty acids
- therapeutic combinations
- dgla
- therapeutic
- gla
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 6
- 229940114079 arachidonic acid Drugs 0.000 abstract 3
- 235000021342 arachidonic acid Nutrition 0.000 abstract 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 abstract 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0016045.7A GB0016045D0 (en) | 2000-06-29 | 2000-06-29 | Therapeutic combinations of fatty acids |
| PCT/GB2001/002717 WO2002002105A1 (en) | 2000-06-29 | 2001-06-20 | Therapeutic combinations of fatty acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200200718A EE200200718A (et) | 2004-08-16 |
| EE05148B1 true EE05148B1 (et) | 2009-04-15 |
Family
ID=9894724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200718A EE05148B1 (et) | 2000-06-29 | 2001-06-20 | Rasvhapete terapeutilised kombinatsioonid |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6479544B1 (pt) |
| EP (1) | EP1296670B1 (pt) |
| JP (1) | JP2004501969A (pt) |
| KR (1) | KR20030016306A (pt) |
| CN (1) | CN100469363C (pt) |
| AT (1) | ATE315388T1 (pt) |
| AU (2) | AU7427601A (pt) |
| BR (1) | BR0112073A (pt) |
| CA (1) | CA2411368C (pt) |
| CZ (1) | CZ20024173A3 (pt) |
| DE (1) | DE60116625T2 (pt) |
| DK (1) | DK1296670T3 (pt) |
| EE (1) | EE05148B1 (pt) |
| ES (1) | ES2256250T3 (pt) |
| GB (1) | GB0016045D0 (pt) |
| HK (1) | HK1050486A1 (pt) |
| HR (1) | HRP20030035A2 (pt) |
| HU (1) | HUP0301107A2 (pt) |
| IL (1) | IL153458A0 (pt) |
| IS (1) | IS2226B (pt) |
| MX (1) | MXPA02012689A (pt) |
| MY (1) | MY117830A (pt) |
| NO (1) | NO329868B1 (pt) |
| NZ (1) | NZ522916A (pt) |
| PL (1) | PL359185A1 (pt) |
| PT (1) | PT1296670E (pt) |
| RU (1) | RU2276975C2 (pt) |
| SK (1) | SK287209B6 (pt) |
| TW (1) | TWI285549B (pt) |
| UA (1) | UA76108C2 (pt) |
| WO (1) | WO2002002105A1 (pt) |
| YU (1) | YU99602A (pt) |
| ZA (1) | ZA200300198B (pt) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| DE10006836B4 (de) * | 2000-04-18 | 2005-03-24 | Bitec Gmbh | Verwendung von Omega-3-Fettsäuren und/oder Verbindungen von Omega-3-Fettsäuren |
| ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| NZ569868A (en) | 2002-09-27 | 2010-01-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| DE10254584A1 (de) * | 2002-11-22 | 2004-06-09 | HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie | Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker |
| GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| FR2856304B1 (fr) * | 2003-06-20 | 2006-03-03 | Natural Product Consulting | Composition pour la prevention des infections du systeme urinaire |
| WO2005018632A1 (en) | 2003-08-18 | 2005-03-03 | Btg International Limited | Treatment of neurodegenerative conditions |
| US7875291B1 (en) | 2003-09-05 | 2011-01-25 | Glu-Pro, Inc. | Composition for managing diabetes, obesity, and hyperlipidemia and associated methods |
| JP4522075B2 (ja) * | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| CA2545190A1 (en) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | Agent for preventing and treating language disorders |
| EP1543735B1 (en) * | 2003-12-20 | 2015-10-07 | Nestec S.A. | Nutritional composition for wound healing |
| CA2551882A1 (en) * | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
| ES2286558T5 (es) | 2004-08-24 | 2013-10-15 | N.V. Nutricia | Composición nutritiva que comprende transgalactooligosacáridos indigeribles y sacáridos de galactosa digeribles |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| JP5503846B2 (ja) * | 2005-01-24 | 2014-05-28 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、ｄｈａを含有する脂肪酸組成物の使用 |
| CA2599112C (en) | 2005-02-14 | 2013-10-22 | Suntory Limited | Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| JP5967855B2 (ja) * | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| US20070154498A1 (en) * | 2005-12-09 | 2007-07-05 | Bortz Jonathan D | Intravenous essential fatty acid emulsion |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607949D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| KR101430214B1 (ko) * | 2006-12-28 | 2014-08-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
| CA2692394A1 (en) * | 2007-07-06 | 2009-01-15 | Seth J. Baum | Fatty acid compositions and methods of use |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| EP2596786B1 (en) | 2009-02-10 | 2019-11-27 | Amarin Pharmaceuticals Ireland Limited | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| RU2538691C2 (ru) | 2009-04-29 | 2015-01-10 | Амарин Фарма, Инк. | Стабильные фармацевтические композиции и способы их применения |
| EP3563842A1 (en) | 2009-04-29 | 2019-11-06 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| LT3318255T (lt) | 2009-06-15 | 2021-05-25 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija |
| CA2775339C (en) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US8865685B2 (en) | 2011-06-30 | 2014-10-21 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| NZ626699A (en) | 2012-01-06 | 2017-03-31 | Omthera Pharmaceuticals Inc | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
| KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-３ 지방산의 조성물 |
| EP2861227A4 (en) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
| EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| KR20210059779A (ko) | 2012-12-06 | 2021-05-25 | 마티나스 바이오파마, 인코포레이티드 | 오메가-3 펜타엔산 조성물 및 사용 방법 |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US20140221676A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating and/or preventing cardiovascular disease |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| EP3065731B1 (en) | 2013-11-05 | 2018-10-24 | Hill's Pet Nutrition, Inc. | Methods and compositions for improving kidney function |
| US11330817B2 (en) * | 2013-12-04 | 2022-05-17 | Nippon Suisan Kaisha, Ltd. | Microbial oil, production method for microbial oil, concentrated microbial oil, and production method for concentrated microbial oil |
| SG10201912145VA (en) | 2014-06-04 | 2020-02-27 | Dignity Sciences Ltd | Pharmaceutical compositions comprising dgla and use of same |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| FI4056176T3 (fi) | 2018-09-24 | 2024-05-30 | Amarin Pharmaceuticals Ie Ltd | Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| KR20220010415A (ko) * | 2020-07-17 | 2022-01-25 | 대봉엘에스 주식회사 | 불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US551680A (en) * | 1895-12-17 | Water-tube steam-generator | ||
| US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
| JPS60132916A (ja) * | 1983-12-21 | 1985-07-16 | Nisshin Oil Mills Ltd:The | 血栓症予防食品または医薬品 |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| GB8714772D0 (en) * | 1987-06-24 | 1987-07-29 | Efamol Ltd | Essential fatty acid compositions |
| GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| US5260067A (en) * | 1988-11-16 | 1993-11-09 | Xu Zheng | Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same |
| JPH04169524A (ja) * | 1990-11-01 | 1992-06-17 | Nissei Marine Kogyo Kk | 血清脂質改善作用を有する組成物 |
| US5658767A (en) * | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
| GB9125602D0 (en) * | 1991-12-02 | 1992-01-29 | Efamol Holdings | Method of preventing reocclusion of arteries |
| JPH05163142A (ja) * | 1991-12-17 | 1993-06-29 | Tokiwa Yakuhin Kogyo Kk | 肝障害の予防または治療用アラキドン酸含有組成物 |
| US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| US5516801A (en) * | 1992-08-21 | 1996-05-14 | Scotia Holdings Plc | Fatty acid treatment for ectopic calcium deposition |
| GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| GB9301446D0 (en) * | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| GB9301629D0 (en) * | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
| CA2119000A1 (en) * | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
| JPH06271464A (ja) * | 1993-03-19 | 1994-09-27 | Tokiwa Yakuhin Kogyo Kk | 消化器系障害の予防または治療用アラキドン酸含有組成物 |
| AUPM906594A0 (en) * | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
| EP0711503A3 (en) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
| GB9423625D0 (en) * | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
| GB9617847D0 (en) * | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
| US5993221A (en) * | 1997-05-01 | 1999-11-30 | Beth Israel Deaconess Medical Center, Inc. | Dietary formulation comprising arachidonic acid and methods of use |
| CN1212867A (zh) * | 1997-09-29 | 1999-04-07 | 宋凤亭 | 防治心脑血管疾病的组合物 |
| DE19757414A1 (de) * | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
| CN1326344A (zh) | 1998-10-15 | 2001-12-12 | Dsm公司 | Pufa增补剂 |
| SE9900941D0 (sv) * | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2000
- 2000-06-29 GB GBGB0016045.7A patent/GB0016045D0/en not_active Ceased
-
2001
- 2001-06-20 NZ NZ522916A patent/NZ522916A/en unknown
- 2001-06-20 CN CNB01811931XA patent/CN100469363C/zh not_active Expired - Fee Related
- 2001-06-20 YU YU99602A patent/YU99602A/sh unknown
- 2001-06-20 PL PL01359185A patent/PL359185A1/xx not_active Application Discontinuation
- 2001-06-20 KR KR1020027017649A patent/KR20030016306A/ko not_active Application Discontinuation
- 2001-06-20 EP EP01940775A patent/EP1296670B1/en not_active Expired - Lifetime
- 2001-06-20 AT AT01940775T patent/ATE315388T1/de active
- 2001-06-20 DE DE60116625T patent/DE60116625T2/de not_active Expired - Lifetime
- 2001-06-20 WO PCT/GB2001/002717 patent/WO2002002105A1/en active IP Right Grant
- 2001-06-20 ES ES01940775T patent/ES2256250T3/es not_active Expired - Lifetime
- 2001-06-20 AU AU7427601A patent/AU7427601A/xx active Pending
- 2001-06-20 CA CA002411368A patent/CA2411368C/en not_active Expired - Fee Related
- 2001-06-20 JP JP2002506727A patent/JP2004501969A/ja active Pending
- 2001-06-20 PT PT01940775T patent/PT1296670E/pt unknown
- 2001-06-20 MX MXPA02012689A patent/MXPA02012689A/es active IP Right Grant
- 2001-06-20 EE EEP200200718A patent/EE05148B1/xx not_active IP Right Cessation
- 2001-06-20 BR BR0112073-5A patent/BR0112073A/pt not_active Application Discontinuation
- 2001-06-20 CZ CZ20024173A patent/CZ20024173A3/cs unknown
- 2001-06-20 UA UA20021210705A patent/UA76108C2/uk unknown
- 2001-06-20 HU HU0301107A patent/HUP0301107A2/hu unknown
- 2001-06-20 DK DK01940775T patent/DK1296670T3/da active
- 2001-06-20 SK SK1816-2002A patent/SK287209B6/sk not_active IP Right Cessation
- 2001-06-20 RU RU2002133098/15A patent/RU2276975C2/ru not_active IP Right Cessation
- 2001-06-20 AU AU2001274276A patent/AU2001274276B2/en not_active Ceased
- 2001-06-20 IL IL15345801A patent/IL153458A0/xx not_active IP Right Cessation
- 2001-06-21 MY MYPI20012947A patent/MY117830A/en unknown
- 2001-06-29 US US09/893,473 patent/US6479544B1/en not_active Expired - Lifetime
- 2001-06-29 TW TW090116201A patent/TWI285549B/zh not_active IP Right Cessation
-
2002
- 2002-11-29 IS IS6644A patent/IS2226B/is unknown
- 2002-12-18 NO NO20026093A patent/NO329868B1/no not_active IP Right Cessation
-
2003
- 2003-01-08 ZA ZA200300198A patent/ZA200300198B/en unknown
- 2003-01-21 HR HR20030035A patent/HRP20030035A2/hr not_active Application Discontinuation
- 2003-04-14 HK HK03102680A patent/HK1050486A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200718A (et) | Rasvhapete terapeutilised kombinatsioonid | |
| ATE349207T1 (de) | Verstärkte wirkung mehrfach ungesättigter fettsäuren | |
| DE60000133D1 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
| EE200300599A (et) | Koensüüm Q ja EPA või muu asendamatu rasvhape | |
| ES2059880T3 (es) | Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias. | |
| DE69720787D1 (de) | Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure | |
| DK1276469T3 (da) | Smagsmaskerende overtrækssammensætning | |
| PT1227820E (pt) | Acidos oligossacarido-aldonicos e sua utilizacao topica | |
| EP1698685A4 (en) | FAT COMPOSITION | |
| FI863976A0 (fi) | Terapeutisk komposition. | |
| TH76781B (th) | การรักษาโรคเบื่ออาหารเหตุจิตใจ (an) และอาการหิวไม่หาย | |
| CA2427289A1 (en) | Fat composition and hexacosanoic acid depressant for oral or enteral administration | |
| AR021830A1 (es) | Utilizacion de acido docosahexaenoico y acido araquidonico para mejorar el crecimiento de bebes anteriores a termino | |
| TH76781A (th) | การรักษาโรคเบื่ออาหารเหตุจิตใจ (an) และอาการหิวไม่หาย | |
| ATE312604T1 (de) | Kombinationspräparat aus omega-3-fettsäuren und konjugierten linolsäuren zur behandlung immunologisch geprägter krankheitsbilder | |
| RU99106551A (ru) | Применение арахидоновой кислоты и/или докозагексаеновой кислоты для получения лекарства для лечения диспраксии | |
| WO2002080974A1 (fr) | Utilisation medicale d'inhibiteur de production de cytokine | |
| TH60770A (th) | สารรวมกรดไขมันเพื่อใช้รักษาโรคได้ | |
| AU2002350620A1 (en) | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | |
| UA39351A (uk) | Препарат для лікування і профілактики захворювань, що супроводжуються підвищеним зсіданням крові |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20110620 |